⚠ Evidence warning: Clinical trials or other evidence do not support the claim, described by integrative practitioners, that combining topical lemon balm, oral lemon balm, L-lysine, vitamin D, lip sunscreen and a standby oral antiviral controls recurrent cold sores for most people without daily prescription suppressive therapy. This page keeps it as a report of what people, websites or other media say.
Lemon Balm Antiviral & HSV Cold Sores
Lemon balm has one well-documented antiviral indication: topical treatment of recurrent herpes labialis (cold sores) caused by herpes simplex virus type 1 (HSV-1). The clinical studies are a 1994 paper by Reinhold Wölbling and Klaus Leonhardt in Germany (Phytomedicine), which reported an open multicentre study of 115 patients and a placebo-controlled double-blind study of 116 patients, and a 1999 single-centre double-blind trial of 66 patients by Koytchev and colleagues, all testing a cream made with a dried lemon balm leaf extract (in the 1999 trial, a standardized lemon balm cream containing 1% extract). The 1999 trial found lower symptom scores than placebo on day 2 of treatment; its authors also described a shorter healing period, less spreading of the infection, and some indication of longer gaps between outbreaks. The mechanism is polyphenol antiviral activity — rosmarinic acid and condensed tannins in lemon balm extract directly bind glycoproteins on the HSV envelope, blocking the attachment-and-entry step before the virus can establish intracellular infection. Topical lemon balm cream is used for mild recurrent cold sores, particularly by people who want a non-prescription option, but it does not replace systemic antivirals (acyclovir, valacyclovir, famciclovir) for severe outbreaks, immunocompromised patients, or HSV in anatomically sensitive locations.
Table of Contents
- HSV-1, Cold Sores, and the Recurrent Outbreak Pattern
- The Wölbling 1994 Studies
- The 1999 Double-Blind Trial and the 2025 Systematic Review
- The Polyphenol Antiviral Mechanism
- Rosmarinic Acid and HSV Attachment Blockade
- Lemon Balm Cream vs Topical Acyclovir Cream
- Lemon Balm Cream vs Oral Antivirals (Valacyclovir)
- Lemon Balm with Lysine and Other Adjuncts
- HSV-2 Genital Herpes — What We Know and Don't
- Beyond HSV: Other Enveloped Viruses
- How the Cream and Antivirals Are Used
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
HSV-1, Cold Sores, and the Recurrent Outbreak Pattern
Herpes simplex virus type 1 (HSV-1) is one of the most prevalent human pathogens — approximately 67% of the global population under 50 has serologic evidence of HSV-1 infection. Primary infection usually occurs in childhood through oral-oral contact and is often asymptomatic. After primary infection the virus establishes lifelong latency in the trigeminal ganglion, periodically reactivating and traveling down the trigeminal nerve to the lip and perioral skin, where it produces the characteristic vesicular eruption known as a cold sore or fever blister.
The recurrent outbreak pattern is highly individual. Some HSV-1-seropositive individuals never have a clinical outbreak. Others have one or two per year. A smaller fraction has frequent recurrences (six or more per year) that may warrant chronic suppressive antiviral therapy. Common reactivation triggers include:
- Psychological stress (the canonical trigger, mediated by stress-induced immunosuppression)
- Ultraviolet (UV) light exposure (sunburned lip, ski trips)
- Fever or other febrile illness (hence "fever blister")
- Menstruation
- Local trauma to the lip area (dental procedures, lip biting)
- Fatigue and sleep deprivation
- Concurrent illness
The natural history of a typical cold sore outbreak follows a predictable arc: prodromal tingling and itching at the site (12-24 hours), erythema and swelling (day 1), vesicle formation (day 2), ulceration as vesicles rupture (day 3-4), crusting (day 5-7), and resolution with no scarring (day 8-12). Topical antivirals work best when started at the prodromal tingling stage, before the vesicles form; once the vesicles are open the treatment window has largely passed. This is the central practical fact that determines what any topical treatment can realistically accomplish.
The Wölbling 1994 Studies
The foundational clinical work on topical lemon balm cream for herpes simplex was published by Reinhold H. Wölbling and Klaus Leonhardt in 1994 in Phytomedicine. It tested a cream made with a specially prepared dried extract of Melissa officinalis leaves in patients with herpes simplex infections.
The paper reported two separate studies: first an open (uncontrolled) multicentre study of 115 patients, then a placebo-controlled, double-blind study of 116 patients. The authors concluded that the two studies supported, in patients, the antiviral activity the extract had shown against herpes simplex in the laboratory, and that treatment was most effective when it was started in the very early stages of the infection. The published summary does not give the size of the effect, such as the number of days of healing saved.
A standardized lemon balm cream based on this kind of extract is sold over the counter in Germany and several other European markets as a non-prescription topical for recurrent herpes labialis.
The 1999 Double-Blind Trial and the 2025 Systematic Review
The second placebo-controlled trial was published by Koytchev, Alken and Dundarov in 1999, also in Phytomedicine. It enrolled 66 patients at one centre, all with a history of recurrent herpes labialis (at least four episodes a year): 34 received a cream containing 1% of a dried lemon balm leaf extract (70:1) and 32 received a placebo cream. The cream was applied to the affected area four times daily for five days.
The main measure was a combined symptom score (complaints, size of the affected area and blisters) on day 2 of treatment, when cold-sore complaints are usually at their worst. The lemon balm group scored significantly better: 4.03 ± 0.33 versus 4.94 ± 0.40 for placebo (mean ± standard error). The authors also wrote that “some indication exists” that the gaps between outbreaks might be longer with the cream.
A 2025 systematic review of herbal creams for cold sores (Anheyer and colleagues) found 7 randomized controlled trials with 1,250 patients in total, covering lemon balm, olive leaf extract, propolis and a combined sage-rhubarb cream. Lemon balm preparations consistently reduced pain and swelling, and some studies also reported significantly smaller lesions than with placebo or acyclovir. The reviewers judged 2 of the 7 trials to be at low risk of bias and 5 to raise some concerns, noted that the total number of patients was small, and found side effects across all the studies minimal or absent.
Together with the 1994 studies, the 1999 trial is the main clinical evidence for topical lemon balm in recurrent HSV-1 cold sores.
The Polyphenol Antiviral Mechanism
The antiviral mechanism of lemon balm extract is fundamentally different from prescription antivirals like acyclovir. Acyclovir is a nucleoside analog that is phosphorylated by the HSV thymidine kinase, then incorporated into the viral DNA being synthesized by HSV DNA polymerase, where it terminates the growing DNA chain. Acyclovir is therefore specifically active inside HSV-infected cells, against actively replicating virus.
Lemon balm's polyphenols act at a completely different step — before the virus enters the host cell. The HSV envelope is studded with glycoproteins (gB, gC, gD, gH, gL) that mediate the multi-step attachment and fusion process by which HSV enters host cells. Initial attachment uses gB and gC binding to heparan sulfate proteoglycans on the host cell surface; subsequent receptor engagement uses gD binding to nectin-1 or herpesvirus entry mediator (HVEM); and final fusion of the viral envelope with the host plasma membrane uses gH/gL.
Polyphenols, particularly the larger ones with multiple phenolic hydroxyl groups, bind non-specifically to glycoproteins through hydrogen bonding to glycan side chains and to amino acid residues. When lemon balm extract is applied to the skin where HSV is replicating, the polyphenols coat the surface of newly released virions, masking the glycoprotein binding sites and physically blocking the attachment-and-entry step on neighboring host cells.
The clinical translation: lemon balm extract does not stop viral replication inside already-infected cells (which acyclovir does), but it blocks the spread of newly produced virus to uninfected neighboring cells — which is what determines how big the lesion gets, how much pain it causes, and how long it takes to heal. Stopping the spread early in the outbreak is what reduces lesion size, pain, and healing time, exactly the endpoints Wölbling measured.
The mechanism also explains why lemon balm works topically but not orally for HSV. Oral lemon balm provides plasma rosmarinic acid concentrations far below what is achievable in the local skin compartment from topical application, and the cold-sore epithelium is not particularly perfused. Topical delivery puts the polyphenol exactly where it needs to be, at concentrations sufficient to coat the local viral pool.
Rosmarinic Acid and HSV Attachment Blockade
Among the lemon balm polyphenols, rosmarinic acid is the leading single contributor to the antiviral effect. In vitro studies have demonstrated that purified rosmarinic acid:
- Inhibits HSV-1 attachment to host cells in plaque-reduction assays at low micromolar concentrations
- Inhibits HSV-2 with similar potency in the same assay format
- Has additive or synergistic activity with acyclovir when tested in combination — the two agents act at different steps of the viral life cycle
- Is active against acyclovir-resistant HSV strains because the mechanism does not depend on thymidine kinase phosphorylation
- Inhibits other enveloped viruses including HIV-1 (in cell-culture systems), influenza A, respiratory syncytial virus, and several herpesvirus family members — suggesting the attachment-blockade mechanism is broadly applicable to enveloped viruses though the clinical translation has only been demonstrated for topical HSV
The activity is not exclusive to rosmarinic acid — condensed tannins, caffeic acid, and the volatile monoterpenes (citral specifically) all contribute additively in whole-extract testing. The whole-extract activity is consistently stronger than any single isolated constituent, suggesting that the synergistic combination is what makes the clinical lemon balm cream effective.
The Schnitzler 2008 paper in Phytomedicine specifically tested lemon balm essential oil against HSV-1 and HSV-2 in plaque-reduction assays on monkey kidney cells (a cell-culture study). Half of plaque formation was blocked at very high dilutions of the oil — 0.0004% for HSV-1 and 0.00008% for HSV-2. At concentrations that did not harm the cells, plaque formation fell by 98.8% for HSV-1 and 97.2% for HSV-2, and higher concentrations abolished infectivity nearly completely. The effect came from treating the virus with the oil before it infected the cells, not after the virus had entered them. The essential oil mechanism appears to involve direct disruption of the viral envelope by the monoterpenes, in addition to the polyphenol attachment-blockade mechanism in the aqueous/ethanolic extract.
Two later cell-culture studies by the same research group show where the water extract acts. When the extract was added to cells that were already infected with HSV-1, it had no antiviral effect. Mixed with free virus, it was strongly virucidal (it inactivated the virus) at concentrations as low as 1.5 µg/mL, while its single phenolic compounds — caffeic acid, p-coumaric acid and rosmarinic acid — needed about 100 times higher concentrations for similar results; the extract and rosmarinic acid also blocked the virus from attaching to cells (Astani 2012). Against two acyclovir-resistant HSV-1 strains taken from patients, the extract acted directly on free virus particles at 50% inhibitory concentrations (IC50) of 0.13 and 0.23 µg/mL, and it blocked entry of the virus into cells by 96%, compared with 80% for drug-sensitive virus (Astani 2014).
Lemon Balm Cream vs Topical Acyclovir Cream
Topical acyclovir cream (5%, sold in the US and many other countries) is the conventional non-prescription topical for HSV-1 cold sores in Europe (it requires prescription in the US). Compared to topical acyclovir, lemon balm 1% cream:
- Has a different mechanism — attachment blockade vs nucleoside-analog chain termination. The two are at least theoretically complementary, though no formal combination trial has been conducted.
- Has no published healing-time figure to set against acyclovir — the summaries of the lemon balm trials report symptom scores, not days of healing saved; the 2025 systematic review found that some lemon balm studies reported significantly smaller lesions than with placebo or acyclovir
- Works against acyclovir-resistant HSV in cell culture — an important advantage in immunocompromised patients with chronic acyclovir exposure who may develop resistant strains
- Has a different tolerability profile — both are well-tolerated; lemon balm has a pleasant lemon aroma; acyclovir cream is odorless and slightly less acceptable to some patients due to texture
- Is non-prescription in most markets where it is available — the principal practical advantage in countries where topical acyclovir requires prescription
- Costs more per gram in many markets than generic acyclovir cream where the latter is over-the-counter (OTC)
The choice often comes down to preference, since neither cream has been shown to be better than the other. For more aggressive outbreaks, clinical reviews describe oral antiviral therapy as the standard treatment, whichever topical is used.
Lemon Balm Cream vs Oral Antivirals (Valacyclovir)
Oral antiviral therapy is the clinical standard for moderate-to-severe HSV-1 outbreaks and for patients with frequent recurrences (six or more per year). The three U.S. Food and Drug Administration-approved oral antivirals for HSV are:
- Acyclovir — the original; requires 5 times daily dosing for cold sores
- Valacyclovir — the L-valine prodrug of acyclovir; far better oral bioavailability allows twice-daily or single-dose protocols. The one-day regimen on the U.S. label — 2 grams twice in one day, taken 12 hours apart, started at the earliest symptom of a cold sore (tingling, itching or burning) — was tested in two randomized, placebo-controlled trials (Spruance 2003). The label states that its effectiveness has not been established once a papule, blister or ulcer has formed
- Famciclovir — the prodrug of penciclovir; similar profile to valacyclovir
In the first of the two Spruance 2003 valacyclovir trials, the one-day course shortened the median cold-sore episode by 1.0 day compared with placebo (0.5 day for a two-day course; mean reductions 1.1 and 0.7 days), and time to healing and to the end of pain were also significantly shorter. The share of people in whom the cold sore was stopped from developing rose by 6.4% and 8.5% over placebo, differences that were not statistically significant; the second trial gave similar results. Clinical reviews describe oral antivirals as the standard treatment for:
- Severe or extensive outbreaks
- Frequent recurrent outbreaks (six or more per year) — either episodic or daily chronic suppressive therapy
- HSV in anatomically sensitive locations (eye, genital, anywhere near mucous membrane)
- Immunocompromised patients (human immunodeficiency virus (HIV), transplant, malignancy, immunosuppressive medications)
- Suppressive therapy in pregnant women near term to prevent neonatal HSV transmission
- Erythema multiforme triggered by HSV outbreaks
Practitioners describe topical lemon balm cream as an option for:
- Mild to moderate recurrent cold sores in immunocompetent patients
- Patients who prefer non-prescription options
- Adjunct to oral antiviral therapy (the topical may provide additional local benefit beyond the systemic drug)
- Patients with acyclovir intolerance or contraindications
- Prophylactic application during high-risk periods (ski trips, dental procedures, periods of high stress) for patients with predictable triggers
The two are not mutually exclusive. Practitioners describe people with frequent severe cold sores using oral valacyclovir for systemic antiviral effect plus topical lemon balm for local symptom relief and additional attachment blockade.
Lemon Balm with Lysine and Other Adjuncts
Several other non-prescription approaches are described for reducing HSV recurrences alongside topical lemon balm, with evidence of varying strength:
- L-lysine supplementation — oral L-lysine 1,000-3,000 mg/day appears to reduce HSV recurrence frequency in some patients. The proposed mechanism is competitive inhibition of arginine uptake (HSV requires arginine for protein synthesis), though the clinical evidence is mixed. It is mainly taken as a long-term supplement by people with frequent recurrences. See Lysine.
- Dietary arginine reduction — the corollary to L-lysine supplementation; reducing dietary intake of arginine-rich foods (peanuts, almonds, walnuts, chocolate, gelatin) is sometimes recommended during outbreaks though evidence is weak
- Zinc — topical zinc sulfate solutions and zinc oxide creams have some evidence for HSV symptom reduction. Mechanism may involve zinc-dependent inhibition of HSV-1 replication. See Zinc.
- Vitamin D — vitamin D deficiency is associated with increased HSV-1 recurrence frequency in observational studies; some practitioners use vitamin D repletion as an add-on, aiming for a blood level of 25-hydroxyvitamin D [25(OH)D] of 40-60 ng/mL. See Vitamin D3.
- Sunscreen on the lip during high-UV exposure — for people whose recurrences are triggered by ultraviolet light, daily lip sunscreen with a sun protection factor (SPF) of 30 or higher is described as one of the most effective preventive measures
- Stress management — for patients with stress-triggered recurrences, the broader anxiety-management approach including lemon balm taken orally for daily anxiety may reduce recurrence frequency through reduced reactivation triggers
- Sleep optimization — chronic sleep deprivation increases HSV reactivation; addressing underlying sleep difficulty (see Sleep Quality) is described as an add-on
Integrative practitioners describe an approach that combines topical lemon balm for acute outbreaks, oral lemon balm for stress reduction, L-lysine and vitamin D for recurrence prevention, lip sunscreen for ultraviolet protection, and an oral antiviral on standby for severe outbreaks, and report that it covers most patients without chronic suppressive prescription therapy.
HSV-2 Genital Herpes — What We Know and Don't
HSV-2 is the second herpes simplex serotype, primarily associated with genital herpes infection. HSV-2 establishes latency in the sacral ganglia rather than the trigeminal ganglion, reactivating along sacral nerve roots to produce genital outbreaks. HSV-1 can also cause genital herpes when transmitted oral-genital, and increasingly does so in younger populations.
The clinical management of HSV-2 genital herpes differs from HSV-1 cold sores in several important ways:
- Outbreaks are typically more painful and more disabling
- Anatomic location is more sensitive and topical creams are less practical
- Transmission risk to sexual partners is the dominant clinical concern, regardless of symptom severity
- Chronic suppressive oral antiviral therapy (valacyclovir 500 mg once daily, or 1 gram daily for more frequent recurrences) is the standard of care for transmission reduction
- Pregnancy implications — neonatal HSV from active maternal genital lesions at delivery is a medical emergency, and suppressive antiviral therapy in late pregnancy is standard for women with known genital HSV
Lemon balm's role in HSV-2 management is much more limited than in HSV-1. The published summary of the original Wölbling studies does not report separate results for genital herpes, and the formulation (creams designed for the lip) is not ideal for genital application. The in vitro antiviral activity is comparable between HSV-1 and HSV-2 (Schnitzler 2008), but the clinical trial evidence in actual genital herpes is sparse.
For most patients with HSV-2 genital herpes, clinical reviews describe oral antiviral therapy as the standard approach — episodic for infrequent outbreaks, chronic suppressive for frequent outbreaks or for partners who want to minimize transmission risk. Topical lemon balm is used by some as an adjunct for local symptom relief; it is not a substitute for systemic antiviral therapy in this indication.
Beyond HSV: Other Enveloped Viruses
The attachment-blockade mechanism of lemon balm polyphenols is in principle applicable to any enveloped virus with surface glycoproteins. In vitro testing has documented activity against several other clinically relevant viruses:
- Varicella-zoster virus (VZV) — the same herpesvirus family as HSV; in vitro inhibition is comparable. No clinical trials in shingles to date.
- Human immunodeficiency virus type 1 (HIV-1) — in a 2008 laboratory study, water extracts of lemon balm, peppermint and sage blocked HIV-1 infection in cell lines, immune cells (macrophages) and tonsil tissue kept alive outside the body, with half the infection blocked at concentrations as low as 0.004%. The extracts acted on free virus particles: they made the particles denser and sharply impaired their entry into cells, while exposing virus already bound to cells, or the cells alone, had virtually no effect. No clinical translation
- Influenza A virus — in vitro inhibition of various influenza subtypes; no clinical trials
- Respiratory syncytial virus (RSV) — in vitro inhibition; no clinical translation
- Various other herpesviruses — human herpesviruses 6 and 7 (HHV-6, HHV-7), Epstein-Barr virus (EBV) all show in vitro sensitivity to rosmarinic acid
The general principle is that an enveloped virus is more susceptible to polyphenol antiviral activity than a non-enveloped virus (because the polyphenols target envelope glycoproteins). Non-enveloped viruses like rhinovirus (common cold), poliovirus, and norovirus are not meaningfully affected by lemon balm extract. In the 2008 HIV study, the extracts worked against several viruses that carry an envelope but not against a non-enveloped adenovirus.
The translation from in vitro activity to clinical benefit has not been adequately studied for any indication other than HSV-1 cold sores. Claims of lemon balm efficacy against other viral infections rest on laboratory data — the in vitro data are interesting and mechanistically supportive, but in vivo trials demonstrating clinical benefit do not exist outside the HSV-1 indication.
How the Cream and Antivirals Are Used
What the trials used, what the valacyclovir label states, and what practitioners describe for adults with a normal immune system and recurrent HSV-1 cold sores:
- At the first tingling or itching — in the 1999 double-blind trial, a cream containing 1% lemon balm leaf extract was applied to the affected area four times daily for five days, and the 1994 authors found treatment most effective when it was started in the very early stages of an outbreak. Practitioners describe a standardized 1% lemon balm extract cream reapplied 4-5 times daily through the outbreak
- When an oral antiviral is added (severe pain, large lesion, sensitive location, history of severe outbreaks) — the valacyclovir label for cold sores lists 2 g by mouth twice in one day, taken 12 hours apart and started at the earliest symptom; practitioners describe keeping the topical cream going alongside it
- Frequent outbreaks (six or more per year) — this is the situation in which daily (chronic suppressive) oral antiviral therapy is used; topical lemon balm is then an add-on only
- Prevention during predictable triggers — some people apply lemon balm cream 2-3 times daily during high-risk periods (a planned ski trip, a dental procedure, a period of high stress) and report fewer breakthrough outbreaks
- Underlying recurrence reduction — practitioners address the triggers: L-lysine supplementation for recurrences, vitamin D repletion when levels are low, lip sunscreen for ultraviolet-triggered outbreaks, and stress reduction (oral lemon balm taken daily plus other anxiety-reducing measures) for stress-triggered outbreaks
- Application technique — the usual technique is a thin layer over the tingling area and the surrounding 5-10 mm of skin. A shared tube can pass the virus to other people or to other parts of one's own skin, hands carry the virus unless they are washed before and after applying, and touching the eye after touching the lip can carry the virus to the eye
- Duration of treatment — the cream is usually applied until the lesion has fully crusted and resolved, typically 5-10 days; the 1999 trial used 5 days
- Signs that are treated as needing medical care — HSV in or near the eye, large lesions that are not resolving by day 7-10, fever or whole-body symptoms, recurrent severe outbreaks, and signs of a secondary bacterial infection
Cautions and Drug Interactions
- Eye exposure — lemon balm cream is made for the lip, not for the eye or eyelid. Herpes of the eye (HSV keratitis, an infection of the cornea) is a sight-threatening infection that eye services treat as urgent with prescription antiviral therapy; topical lemon balm is not a treatment for it.
- Open broken skin and large lesions — mild local stinging when applied to actively weeping vesicles is common and not concerning. Severe burning or worsening is unusual, and it is a reason people stop the cream.
- Contact sensitization — rare but possible; documented in case reports for some lemon balm preparations. A skin reaction is a reason people stop the cream, and patch testing can identify the cause.
- Pregnancy and lactation — topical use in pregnancy is generally regarded as low-risk given the minimal systemic absorption from topical application; however, the European Medicines Agency (EMA) monograph recommends conservative use in pregnancy and lactation in the absence of formal safety trials
- Immunocompromised patients — topical lemon balm is used only as an add-on, not as a replacement for prescription antiviral therapy, in patients with human immunodeficiency virus, transplant, malignancy, immunosuppressive drug therapy, or pregnancy near term
- Differentiate from other lip lesions — not all lip lesions are HSV. Angular cheilitis (often candidal), bacterial impetigo, allergic contact dermatitis, traumatic lesions, and squamous cell carcinoma can all present with lip lesions. A lip sore that does not follow the usual cold-sore pattern may be one of these conditions, which are diagnosed and treated differently from HSV.
- Children — topical application is generally regarded as low-risk in children with confirmed recurrent HSV-1; the risks described are swallowing the cream and getting it in the eye
- Drug interactions — topical lemon balm has minimal systemic absorption and no clinically significant drug interactions at typical application doses
Key Research Papers
- Wölbling RH, Leonhardt K (1994). Local therapy of herpes simplex with dried extract from Melissa officinalis. Phytomedicine. — PubMed PMID: 23195812
- Koytchev R, Alken RG, Dundarov S (1999). Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis. Phytomedicine. — PubMed PMID: 10589440
- Schnitzler P, Schuhmacher A, Astani A, Reichling J (2008). Melissa officinalis oil affects infectivity of enveloped herpesviruses. Phytomedicine. — PubMed PMID: 18693101
- Astani A, Reichling J, Schnitzler P (2012). Melissa officinalis extract inhibits attachment of herpes simplex virus in vitro. Chemotherapy. — PubMed PMID: 22377592
- Mazzanti G, Battinelli L, Pompeo C, Serrilli AM, Rossi R, Sauzullo I, et al. (2008). Inhibitory activity of Melissa officinalis L. extract on herpes simplex virus type 2 replication. Natural Product Research. — PubMed PMID: 19023806
- Astani A, Navid MH, Schnitzler P (2014). Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by Melissa officinalis extract. Phytotherapy Research. — PubMed PMID: 24817544
- Allahverdiyev A, Duran N, Ozguven M, Koltas S (2004). Antiviral activity of the volatile oils of Melissa officinalis L. against herpes simplex virus type-2. Phytomedicine. — PubMed PMID: 15636181
- Reichling J, Schnitzler P, Suschke U, Saller R (2009). Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties — an overview. Forschende Komplementärmedizin. — PubMed PMID: 19420953
- Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. (2003). High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores. Antimicrobial Agents and Chemotherapy. — PubMed PMID: 12604544
- Worrall G (2009). Herpes labialis. BMJ Clinical Evidence. — PubMed PMID: 21726482
- Cernik C, Gallina K, Brodell RT (2008). The treatment of herpes simplex infections: an evidence-based review. Archives of Internal Medicine. — PubMed PMID: 18541820
- Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology. — PubMed PMID: 27167460
- Anheyer M, Cramer H, Ostermann T, Längler A, Anheyer D (2025). Herbal medicine for treating herpes labialis: a systematic review. Journal of Integrative and Complementary Medicine. — PubMed PMID: 40526027
- Geuenich S, Goffinet C, Venzke S, Nolkemper S, Baumann I, Plinkert P, Reichling J, Keppler OT (2008). Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology. — PubMed PMID: 18355409